Edwards Lifesciences Co. (NYSE:EW) Position Trimmed by Mizuho Securities USA LLC

Mizuho Securities USA LLC trimmed its stake in Edwards Lifesciences Co. (NYSE:EW) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,062 shares of the medical research company’s stock after selling 7,396 shares during the quarter. Mizuho Securities USA LLC’s holdings in Edwards Lifesciences were worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in EW. LRI Investments LLC bought a new stake in Edwards Lifesciences in the first quarter worth approximately $67,000. Lazard Asset Management LLC lifted its position in shares of Edwards Lifesciences by 89.6% in the first quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company’s stock worth $8,946,000 after buying an additional 44,257 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Edwards Lifesciences by 8.3% during the 1st quarter. Bellevue Group AG now owns 1,103,136 shares of the medical research company’s stock valued at $105,416,000 after acquiring an additional 84,138 shares during the last quarter. Finally, Kennedy Capital Management LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $2,440,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.49 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $41.58 billion, a P/E ratio of 10.17, a PEG ratio of 3.95 and a beta of 1.12. The company’s 50-day simple moving average is $67.70 and its 200 day simple moving average is $75.73.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the business earned $0.59 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. UBS Group lowered their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Evercore ISI dropped their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $75.67.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 over the last three months. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.